A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

Background A Phase I study to determine the maximum tolerated dose (MTD) and pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family Blocker, administered orally once daily in a 3-week-on/1-week-off dosing schedule. Methods Patients with advanced solid tumors received single-agent...

Full description

Bibliographic Details
Main Authors: Marshall, John, Hwang, Jimmy, Eskens, Ferry A. L. M., Burger, Herman, Malik, Shakun, Uttenreuther-Fischer, Martina, Stopfer, Peter, Ould-Kaci, Mahmoud, Cohen, Roger B., Lewis, Nancy L
Format: Online
Language:English
Published: Springer US 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589659/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589659/

Similar Items